SCHEMBL30794818

SCHEMBL30794818

Cc1cc(N2CCOCC2)nc(C(C)(C)C)c1C(=O)NCc1cccc(F)c1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SRC P12931 1/20 0.47
NAPEPLD Q6IQ20 1/20 0.44
PIK3CA P42336 4/20 0.44
PIK3CB P42338 3/20 0.44
PIK3CD O00329 2/20 0.44
PIK3CG P48736 2/20 0.43
STAT6 P42226 1/20 0.42
KLKB1 P03952 1/20 0.42
KLK1 P06870 1/20 0.42
TP53 P04637 1/20 0.42
BRAF P15056 1/20 0.42
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41
AKT1 P31749 1/20 0.41
GBA1 P04062 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2128983 1.00 SRC (0.47) SRCNAPEPLDPIK3CAPIK3CBPIK3CD
SCHEMBL30795947 0.88 SRC (0.49) SRCNAPEPLDPIK3CAPIK3CBPIK3CD
SCHEMBL2133149 0.88 SRC (0.49) SRCNAPEPLDPIK3CAPIK3CBPIK3CD
SCHEMBL2134192 0.88 SRC (0.49) SRCNAPEPLDPIK3CAPIK3CBPIK3CD
SCHEMBL2129359 0.88 SRC (0.49) SRCNAPEPLDPIK3CAPIK3CBPIK3CD
SCHEMBL2129738 0.86 SRC (0.46) SRCNAPEPLDPIK3CAPIK3CBPIK3CD
SCHEMBL30795803 0.86 SRC (0.47) SRCNAPEPLDPIK3CAPIK3CBPIK3CD
SCHEMBL2129743 0.86 SRC (0.47) SRCNAPEPLDPIK3CAPIK3CBPIK3CD
SCHEMBL2130397 0.85 SRC (0.47) SRCNAPEPLDPIK3CAPIK3CBPIK3CD
SCHEMBL2129755 0.85 NAPEPLD (0.48) SRCNAPEPLDPIK3CAPIK3CBPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 EP disclosed
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 WO disclosed